CompanyDrug

InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC

CompanyDrug

Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China

Company

Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results

CompanyDrug

Hepalink’s Enoxaparin Sodium Injection Receives Marketing Approval in New Zealand

CompanyDrug

IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial

CompanyPolicy / Regulatory

WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer

Policy / Regulatory

China’s National Joint Procurement Office Announces Renewal of Insulin Procurement Contracts Valued at $1.59 Billion

CompanyPolicy / Regulatory

FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy

CompanyPolicy / Regulatory

WuXi AppTec Denies Unauthorized IP Transfer Allegations Amidst Strong Financial Performance

CompanyDrug

Genor Biopharma’s Lerociclib Accepted for Review by China’s NMPA for Breast Cancer Treatment

CompanyDeals

BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009

Company

RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments